FASLG and cancer: Numerous ex vivo studies of circulating lymphocyte subsets in patients with various types of cancer have suggested that the peripheral T lymphocyte depletion frequently observed in patients with advanced cancers [23] is induced by EV-mediated signaling via the death receptor/ligands, specifically Fas/FasL and TRAILR/TRAIL [24].